Gly-Phe |A-naphthylamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Gly-Phe |A-naphthylamide
• 英文别名: 2-[(2-aminoacetyl)amino]-N-naphthalen-2-yl-3-phenylpropanamide
• 化学式: C₂₁H₂₁N₃O₂
• 分子量: 347.4
• InChiKey: YABDXPBHLDPMOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  84.2
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Methods and compositions for restoring homeostatic capacity of a subject
  申请人：Palo Alto Investors

  公开号：US10835134B2

  公开（公告）日：2020-11-17

  Methods of restoring homeostatic capacity of a subject are provided. Aspects of the invention further include compositions, systems and devices for practicing the methods. The methods and compositions described herein find use in a variety of applications. Aspects of certain embodiments of the methods include modulating a subject's autonomic nervous system in a manner sufficient to restore the homeostatic capacity of the subject. Aspects of other embodiments of the invention include administering to the subject an amount of an apoptosis modulator effective to at least partially restore homeostatic function of the neuroendocrine system of the subject.

  本发明提供了恢复受试者体内平衡能力的方法。本发明的各个方面还包括用于实施这些方法的组合物、系统和设备。本文所述的方法和组合物可用于多种应用。本发明方法的某些实施方案包括以足以恢复受试者平衡能力的方式调节受试者的自律神经系统。本发明其他实施方案的方面包括向受试者施用一定量的细胞凋亡调节剂，其有效量至少可部分恢复受试者神经内分泌系统的平衡功能。
• MODULATION OF FUNCTION OF IMMUNE EFFECTOR CELLS
  申请人：Oslo Universitetssykehus HF

  公开号：EP3515477A1

  公开（公告）日：2019-07-31
• Methods and Compositions for Restoring Homeostatic Capacity of a Subject
  申请人：Palo Alto Investors

  公开号：US20150359888A1

  公开（公告）日：2015-12-17

  Methods of restoring homeostatic capacity of a subject are provided. Aspects of the invention further include compositions, systems and devices for practicing the methods. The methods and compositions described herein find use in a variety of applications.
• GALECTINS CONTROL MTOR IN RESPONSE TO ENDOMEMBRANE DAMAGE AND PROVIDE A MECHANISM AND TARGET FOR THE TREATMENT OF AUTOPHAGY-RELATED DISEASES
  申请人：STC. UNM

  公开号：US20210069295A1

  公开（公告）日：2021-03-11

  The present invention is directed to the discovery that Galectins and in particular, Galectin-8 and Galectin-9 control mTor response (Galectin-8 is a mTOR inhibitor and Galectin-9 is modulator/upregulator of AMPKinase) to endomembrane damage and these compositions can be used, either alone or together, optionally in combination with a lysomotropic agent and other bioactive agents as compositions for the treatment of autophagy-elated diseases. The present invention is directed to pharmaceutical compositions and methods for treating autophagy-related diseases as described herein.
• [EN] MODULATION OF FUNCTION OF IMMUNE EFFECTOR CELLS<br/>[FR] MODULATION DE LA FONCTION DE CELLULES EFFECTRICES IMMUNITAIRES
  申请人：UNIV OSLO HF

  公开号：WO2018055152A1

  公开（公告）日：2018-03-29

  The present invention is directed to methods of modulating the function of granular immune effector cells. It has been discovered that the secretory lysosomes of immune effector cells function as signalling hubs which direct effector functionality of the cells. By increasing or decreasing the signalling potential of the secretory lysosomes of the immune effector cells, effector functionality may be enhanced or reduced, and thus activity of the immune effector cell increased or decreased, respectively. The present invention provides methods for preparing immune effector cells for adoptive cell transfer, in which the cells are contacted with an agent which increases the signalling potential of secretory lysosomes, thus providing enhanced immune effector cells.